Lv1
60 积分 2025-03-17 加入
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 “DICIPLE” Phase III trial
1个月前
已关闭
CerS6 triggered by high glucose activating the TLR4/IKKβ pathway regulates ferroptosis of LO2 cells through mitochondrial oxidative stress
2个月前
已完结
Targeting ferroptosis and mitophagy with neutrophil-inspired nanozyme for Parkinson's disease therapy
3个月前
已完结
Successful reperfusion for better outcomes in medium vessel occlusion: Penumbral salvage versus infarct volume reduction
7个月前
已完结
皖公网安备34019202002308
